BioArctic AB (BIOAB:SS) will collaborate with Eisai (OTCPK:ESALY) on research aimed at further characterizing the mechanism of action of Alzheimer’s disease candidate BAN2401, in-licensed by Eisai in December 2007.
Under the terms of the agreement, Eisai will pay up to €3.25M (~SEK 34M) to BioArctic under the partnership, expected to run through June 2021.
Results will be submitted for presentation at future medical conferences.
Eisai is currently conducting a large-scale Phase 3 study, CLARITY AD, with collaboration partner Biogen (BIIB -1.1%) evaluating BAN2401 in patients with early Alzheimer’s. The estimated primary completion date is February 2022.
BAN2401 is a humanized monoclonal antibody that selectively binds to (and eliminates) toxic amyloid beta aggregates in the brain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.